Relationship between XXXX and health care costs in @entity712 .

@entity1 @entity712 @entity417
BACKGROUND: @entity417 is associated with higher morbidity and mortality in @entity1 with @entity712 ( @entity712 ), but its implications for heath care costs are not well described. METHODS AND RESULTS: We analyzed data on 1056 @entity1 with symptomatic @entity712 seen at Duke University between 2002 and 2006. Health care costs were obtained from the hospital cost accounting data system. Adjustments for censoring and covariate imbalance were performed using inverse probability weighted estimators and propensity scores. The prevalence of @entity417 was 32%. Unadjusted mortality at 3 years was 50.3% in anemic versus 26.5% in non-anemic @entity1 . The adjusted costs per year alive were  22,926 for @entity1 with @entity417 and  17,189 for those without (P=.04). For those with ejection fraction <or=40% adjusted costs per year alive were  32,914 for anemic versus  18,423 for non-anemic @entity1 (P=.01). CONCLUSIONS: @entity417 in @entity712 @entity1 was independently associated with greater total costs after accounting for differences in survival, but appeared to be confined primarily to @entity1 with low ejection fraction. These results provide a framework for understanding the economic implications of therapies for @entity417 in @entity712 , and suggest that targeting @entity1 with impaired systolic function has the potential to most favorably affect costs.
